NONashwa Naguib Omar

Nashwa Naguib Omar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nashwa Naguib Omar has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Hossam Abdelghaffar

    Department of ENT, Faculty of Medicine, Helwan University, Helwan, Egypt; Secretary General of the Supreme Council for University Hospitals, Cairo, Egypt

    4 shared publications
  • Ghada Ismail

    Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Director of Reference Laboratory of the Egyptian University Hospitals, Cairo, Egypt

    3 shared publications
  • Marwa Salah Mostafa

    Department of Medical Microbiology and Immunology, Faculty of Medicine, Cairo University, Cairo, Egypt

    3 shared publications
  • Noha Alaa Eldin Fahim

    Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

    3 shared publications
  • Rania Abdel Halim

    Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

    3 shared publications
  • Ahmed Elshafei

    Theodor Belharz Research Institute, Ministry of Higher Education and Scientific Research, Giza, Egypt

    2 shared publications

Latest Publications

  • Open Access

    The Impact of Sputnik SARS-CoV-2 Vaccines on Antibody Response in the Egyptian Population

    by Ghada Ismail, Dalia Abdelhamid, Marwa Salah Mostafa, Noha Alaa Eldin Fahim, Ahmed Elshafei, Hossam Abdelghaffar, Nashwa Naguib, Omnia Taher, Menna Asker

    BACKGROUND: The coronavirus disease 2019 (COVID-2019) causes the severe contagious acute respiratory syndrome. Therefore, massive vaccination campaign is mandatory to control the spread. Sputnik COVID-19 vaccines induce immunity through different mechanisms involving antibody response that bind to the spike protein to neutralize the viral entry into the cells. AIM: This study aims to compare the titers of specific antibodies in the pre- and post-vaccination sera in the vaccinated Egyptian population to evaluate the efficacy of the sputnik vaccine. METHODS: Samples were collected from 205 adult volunteers receiving the Sputnik vaccine in the Reference Laboratory of Egyptian University Hospitals. Samples were collected before vaccination and within 1, 2, or 3 months after receiving two doses of Sputnik SARS-CoV-2 vaccines from August to October 2021, serum samples collected were tested by quantitative chemiluminescent immunoassay using (Mindray CL-960i chemiluminescence analyzer, India) at the Reference laboratory of Egyptian University Hospitals for neutralizing antibodies, anti-spike antibodies, and total antibody levels before and after vaccination. RESULTS: The results of the 205 paired samples illustrated that there was a statistically significant difference between pre- and post-vaccination antibody levels with a p-value of (< 0.001) indicating that the vaccine produced significantly high levels of antibodies. CONCLUSION: COVID-19 Sputnik vaccines induce immunity through an antibody response that binds to the virus to neutralize its entry into cells. Our study showed a significant increase in the measured post-vaccination levels of the three antibodies among the enrolled volunteers compared to the basal pre-vaccination level and thus sputnik vaccine protects against SARS-CoV-2 infections.

  • Open Access

    Comparative Evaluation of Different SARS-CoV-2 Rapid Point-of-Care Antigen Tests with SARS-CoV-2 PCR for Diagnosis of COVID-19

    by Ghada Ismail, Dalia H. Abdelhamid, Rania Abdel Halim, Marwa Salah Mostafa, Hossam Abdelghaffar, Noha Alaa Eldin Fahim, Ahmed Elshafei, Menna Asker, Nashwa Naguib Omar

    BACKGROUND: Detection of positive 2019-nCoV nucleic acids by real-time reverse transcriptase-polymerase chain reaction (rRT-PCR)-based assays performed on the upper and lower respiratory samples remains the gold standard for the diagnosis of COVID-19. However, antigen-detecting rapid diagnostic tests can offer a faster (15–30 min) and less expensive way to diagnose active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection than nucleic acid amplification tests. AIM: Hence, the present study aimed to compare and evaluate the results of different SARS-CoV-2 rapid point-of-care antigen tests with SARS-CoV-2 PCR as a reference method. METHODS: Sixty-five nasopharyngeal swab specimens were collected from attendees of the Reference Laboratory of Egyptian university hospitals. The samples were placed in viral transport medium for RNA extraction. The remaining part of the suspension was stored at −70°C until use for COVID-19 antigen testing. All samples were processed for the COVID-19 Ag rapid test and RT-PCR simultaneously. RESULTS: RT-PCR assay revealed 46 (70.8%) positive samples and 19 (29.2%) negative samples for COVID-19. All eight rapid antigen assays indicated specificity and positive predictive value of 100% each. As for the other parameters, the sensitivity, negative predictive value (NPV), and accuracy ranged from 43.8 to 93.8, 33.3 to 90, and 60 to 96, respectively. Biozak exhibited the best performance with the highest sensitivities 91.3, 81.8, and 93.75, respectively, while Viro and Standard Q were the worst among the tested kits with sensitivity, NPV, and accuracy of 50, 33.3, and 60 each. Regarding the relationship between the viral load of COVID-19 detected by RT-PCR and the results of the eight rapid antigen tests (RAT), we deduced that the higher the viral load, the better the sensitivity observed. CONCLUSION: The RATs used, in our study, exhibited heterogeneous diagnostic performance, where some of them showed very promising results in comparison to the reference RT-PCR assay.

  • Open Access

    Comparison of Abbott ID NOW COVID-19 Rapid Molecular Assay to Allplex 2019-nCoV and VIASURE SARS-CoV-2 Detection in Nasal Swabs

    by Ghada Ismail, Dalia Abdelhamid, Rania Abdelhalim, Marwa Salah Mostafa, Hossam Abdelghaffar, Noha Alaa Eldin Fahim, Ahmed Elshafei, Nashwa Naguib

    BACKGROUND: Readily available, accurate, and rapid diagnostic technologies are of high priority to contain emerging and re-emerging pandemics and to properly allocate personal protective equipment usage and preventing nosocomial spread with subsequent community transmission. Detection of positive 2019-nCoV nucleic acids by real-time reverse transcriptase-polymerase chain reaction (rRT-PCR)-based assays remains the gold standard for COVID-19 diagnostics. However, these assays take an average over 3–5 h to generate results and the PCR tests require certified laboratories, expensive equipment, and trained technicians to operate. Therefore, there is an urgent need for rapid point of care molecular tests that can be readily used in a healthcare setting that generates reliable results within few hours. Those tests should provide reliable results in the setting to facilitate the diagnosis and rapid decision-making. AIM: The present study aimed to evaluate the diagnostic performance of Abbott ID NOW SARS-CoV-2 compared to two gold standard assays (Allplex 2019- nCoV and VIASURE SARS-CoV-2) and to detect the relation between viral load and the sensitivity of ID NOW SARS-CoV-2 assay. METHODS: A total of 86 and 42 nasopharyngeal swabs collected from patients attending the Reference Laboratory of Egyptian University Hospitals during the period from January 2022 to May 2022, were tested by our reference methods of RT-PCR for COVID-19 detection; VIASURE kit and Allplex kits, respectively. Corresponding dry nasal swabs were collected from the same patients for ID NOW SARS-CoV-2 ribonucleic acid (RNA) detection assay. RESULTS: As regards the results of the 86 nasopharyngeal swabs tested by both VIASURE kit and ID NOW, there was a good agreement between both methods (95%) (kappa = 0.924), where the ID NOW method was not able to detect three COVID-19-positive samples (3/86, 5.1%). ID NOW exhibited specificity and sensitivity of 100% and 94.9%, respectively. As for comparing results of ID NOW with Allplex kit, the results of the 42 nasopharyngeal swabs tested by both tests revealed good agreement between both methods (kappa = 0.908). In comparison with Allplex kit, ID NOW exhibited specificity and sensitivity of 90% and 100%, respectively. Regarding the relation between the viral load detected by VIASURE kit and results of the ID NOW test, we found that ID NOW showed a sensitivity of 82.35% in samples with low viral load (CT > 30), while for samples with intermediate (CT: 20–30) and high (CT < 20) viral loads, sensitivity was 100%. CONCLUSION: ID NOW assay in our study exhibited a high diagnostic performance when evaluated with the gold standard RT-PCR methods. Our study further substantiates the high sensitivity of ID NOW in the presence of intermediate and high viral loads detected by molecular RT-PCR SARS-CoV-2 testing. Its analytical performances, combined with the very short 13 min reactional time and the friendly device-guided handling procedure, constitute an additional advantage of ID NOW COVID-19 for setting up a rapid diagnosis within the clinical laboratories and for timely identification of outbreaks allowing for aggressive contact tracing and containment.


  • Open Access

    Incidence of emerging multidrug-resistant organisms and its impact on the outcome in the pediatric intensive care

    by Ahmed R. Rezk, Somaia Abdelhammed Bawady, Nashwa Naguib Omar

    Background: Healthcare-associated infections (HCAI) are a worldwide threat in intensive care units particularly in the pediatric intensive care units with a major cause of morbidity and mortality among this age group. The aim of the study is to determine the prevalence and risk factors predisposing to multidrug-resistant organisms (MDROs) infections among pediatric intensive care unit (PICU) patients at Ain Shams Pediatric University Hospitals as well as determining mortality and morbidity rates along with the length of stay at PICU. Results: Culture results revealed that of the 282 patients evaluated, only 26 (9.2%) were MDROs (half of the affected patients had Acinetobacter species (50%) and the rest of them were free, 256 (90.8%). Our study revealed that the majority of MDROs were isolated from sputum in more than half of the patients 19/32 (59.3%) followed by whole blood in 10/32 (31.2%) and urine in 3/32 (9.4%). Pulmonary system was the most common affected site and was mainly colonized by MDR Acinetobacter (71.4%) followed by MDR Klebsiella (41.6%). Regarding MDR risk factors in our PICU, multivariate logistic regression analyses showed significant relationship between MDROs and age under 1 year (odds ratio [OR] 2.4554; 95% confidence interval [95% CI] (1.072–5.625); p = 0.043) and underlying pulmonary disease (OR 2.417; 95% CI (1.014–5.761); p = 0.592). A statistically significant higher mortality was detected in patients colonized with MDROs 9/26 (34.6%) versus MDROs non-colonized patients 32/256 (12.5%) [P=0.002]. Moreover, MDROs infection has negative significant risk with discharged patients ([OR] 0.269; [95% CI] (0.111–0.656); p = 0.002). Additionally, patients infected with MDROs did have significantly greater PICU stay than those non-infected [median (IQR), 16.5 (10.7–22), 5 (4–8), P=0.00] and have longer ventilation [median (IQR), 15.5 (10–18), 3 (2–10), P=0.00]. Conclusion: Prevalence of MDROs (9.2%) was low among PICU cases at Ain Shams University Hospitals. Most common MDROs were Acinetobacter and Klebsiella followed by pseudomonas species. The frequency of gram-negative organisms is much more common than gram-positive organisms. An increasing rate of antimicrobial resistance with increasing mortality and morbidity among PICU patients is observed worldwide; even for new categories, so, strict infection control programs should be implemented.


  • Open Access

    Current Status and a Future Perspective of COVID-19 in Egypt: Egyptian Reference Laboratory Experience

    by Ghada Ismail, Marwa Salah Mostafa, Hossam Abdelghaffar, Rania Abdel Halim, Nashwa Naguib Omar, Noha Alaa Eldin Fahim

    Currently, the sole global concern is recurring waves of the COVID-19 virus that began in 2020 and is ongoing. This study aimed to compare the trends of COVID-19 infections in Egypt during the different waves. We calculated the COVID-19 positivity rate between March 2020 and the fourth week of April 2021 among those tested at the Reference Laboratory of the Egyptian University Hospitals. We then compared our results with those obtained from the WHO and the Egyptian Ministry of Health and Population websites. A dramatic increase in the positivity rate was observed during May and June 2020 (26.35% and 33.11%, respectively). This was followed by an abrupt reduction in July (11.7%), and flattening until a second increase was noted during November (9.6%), which reached its peak during December (17.8%). However, after the figures declined during January 2021, they began to rise again in February 2021 and continued to increase until the end of April 2021, simulating the first wave data. The analysis of the COVID-19 growth rate from April 1st to the 25th, 2021 revealed a slight downward trend in new cases. Data from both the WHO and the Egyptian Ministry of Health and Population websites showed similar patterns to our results. The third wave of COVID-19 started in Egypt. Analyzing future data can aid in forecasting the COVID-19 epidemic and allow us to use foresight to enact effective measures and strategies to keep this virus under control.


  • Open Access

    Comparative Evaluation of SARS-CoV-2 Rapid Immunochromatographic Test Assays with Chemiluminescent Immunoassay for the Diagnosis of COVID-19

    by Ghada Ismail, Rania Abdel Halim, Marwa Salah Mostafa, Dalia H Abdelhamid, Hossam Abdelghaffar, Nashwa Naguib Omar, Noha Alaa Eldin Fahim

    Background To date, the molecular assay is the gold-standard method for COVID-19 diagnosis. However, they are expensive and complex. There is a pressing necessity for developing other effective diagnostics for SARS‐CoV‐2 patients. Therefore, serological detection of antibodies against SARS‐CoV‐2 might provide a good alternative. Aim We aimed to compare and evaluate seven rapid diagnostic tests with Mindray chemiluminescent automated immunoassay as a reference method for SARS-CoV-2 antibodies detection. Methods: This study included the serum of a total of 49 attendees to the Reference Laboratory of Egyptian university hospitals during the period from April 2021 to May 2021. Anti-Covid-19 antibodies detection in serum samples was performed by Mindray fully automated system as our reference method and seven rapid antibody tests; Wondfo, Vazyme, Dynamiker, Panbio, Artron Maccura and Roche. Results: The chemiluminescent assay revealed 30 (61.2%) positive samples and 19 (38.8%) negative samples for COVID-19 IgG. For COVID-19 IgM, 11 (22.4%) samples were positive and 38 (77.6%) samples were negative. Anti-SARS-CoV-2 antibodies were not detected in any of the PCR negative individuals. The best diagnostic performance was demonstrated by Roche IgG and IgM, and Vazyme IgG and IgM antibody tests followed by Panbio. For Roche, the sensitivity and specificity for IgG and IgM were (83.3%, 89.5%) and (72.7%, 81.6%) respectively. Vazyme showed sensitivity and specificity for IgG and IgM were (77.8%, 85.7%) and (75%, 91.7%) respectively. Regards Panbio, the sensitivity and specificity for IgG and IgM were (63.6%, 87.5%) and (50%, 86.7%) respectively. Cohen’s Kappa values revealed a substantial agreement for Roche IgG, Vazyme IgG and IgM of (0.7076, 0.6250, 0.6667) respectively. The worst agreement was reported for Maccura IgG, Wondfo, and Dynamiker IgM with Cohen’s Kappa values of (0.2508, 0.1893, 0.0313) respectively. Conclusions: Rapid tests in our study exhibited heterogeneous diagnostic performances. Roche, Vazyme, and Panbio antibody tests showed promising results in concordance with our reference method with the best-reported results. On the other hand, the other tests were inferior and failed in providing valid and reliable results. Further studies are necessary to determine the practicality of these tests in different settings and communities.

  • In Vitro Antimicrobial Combinations for Pan-Drug Resistant Acinetobacter Species

    by Nashwa Mohamed Naguib Mahmoud Omar, Samia Abdou Girgis, Sherif Wadie Nashed, Sally Mohamed Saber, Rania Mohamed AbdelHalim

    Background: Pandrug resistant Gram-negative organisms (PDRGNs) have emerged, as a major threat to hospitalized patients. They have been associated with mortality rates ranging from 30 to 70%. Because of the high morbidity and mortality rates of severe pandrug resistant acinetobacter spp infections, combination therapies, as opposed to monotherapy, are suggested. A synergistic effect may be developed when antibiotics are used in combination. Through this synergistic effect, treatment efficacy can be improved and resistance can be prevented. Aim of the work: To investigate the use of in vitro antibiotic synergy test (checkerboard) for pandrug resistant acinetobacter species with a clinical feedback on the most synergistic antimicrobial combination. Materials and Methods: During this study, one hundred isolates of drug resistant acinetobacter species identified by routine culture and sensitivity using disc diffusion susceptibility test, were collected from critically ill patients admitted to Ain Shams University Internal Medicine Intensive Care Units. The isolates were subjected to: (i) Determination of MIC using Vitek 2 automated system to confirm resistance of acinetobacter species to all commercially available antibiotics, (ii) Broth micro-dilution method (BMD) for determination of tigecycline susceptibility, and (iii) Determination of antimicrobial synergy by broth micodilution (Checkerboard method). Results: Vitek 2 system results showed that, all of the 100 isolates were resistant to all antibiotics included in the study. On the other hand, 100% of the isolates were sensitive (S) to Colistin. As regards the results by Broth microdilution antibiotic susceptibility method, all 100 isolates (100%) were resistant to ampicillin/sulbactam, meropenem and ciprofloxacin, whereas 95 isolates (95%) were resistant to amikacin, whereas all 100 isolates (100%) tested were sensitive to tigecycline. The results of the antibiotic combinations were as follows; the activity of ampicillin/sulbactam in combination with amikacin showed synergy in (48%), addition in (42%) and indifference in (10%). The activity of ampicillin/sulbactam in combination with ciprofloxacin showed, synergy in (36%), addition in (52%) and indifference in (12%). The activity of meropenem in combination with amikacin showed, synergy in (26%), addition in (53%) and indifference in (21%). No antagonistic activity was detected between any of the antibiotic combinations used. Conclusion: The prevalence of XDR/PDR resistant Acinetobacter spp. was highest in blood samples (43%) followed by sputum samples (35%) recovered from critically ill patients admitted to Ain Shams University Internal Medicine Intensive Care Units. Vitek 2 system showed that, all of the 100 isolates were resistant to all antibiotics included in the study. On the other hand, 100% of the isolates were sensitive (S) to colistin. Broth microdilution antibiotic susceptibility method showed that, all 100 isolates (100%) were resistant to ampicillin/sulbactam, meropenem and ciprofloxacin, whereas 95 isolates (95%) were resistant to amikacin, whereas all 100 isolates (100%) tested were sensitive to tigecycline, indicating that acinetobacter spp. did not attain resistance to tigecycline yet. The broth microdilution antibiotic synergy test (Checkerboard method), being the reference method for assessing antimicrobial synergy, showed that the highest synergic activity belongs to ampicillin/sulbactam and amkacin (48%), and the lowest synergic activity belongs to meropenem and amikacin (26%).